1. Painful diabetic neuropathy — MSC injection into the affected limb
The most consistent human signal for DPN comes from intramuscular injection of autologous bone-marrow-derived mesenchymal stem cells along the lower-limb nerve tracks. Multiple small-to-mid randomized trials out of centers in Iran, Korea, India, and China have reported reductions in pain VAS, improvements in the Toronto Clinical Neuropathy Score (TCNS), and modest gains in nerve conduction velocity vs sham or standard-of-care at 6–12 months.
- Mechanism: MSCs are believed to act paracrine — releasing neurotrophic factors (NGF, BDNF, VEGF) that support Schwann cells and re-vascularize the vasa nervorum, rather than engrafting as neurons.
- Endpoints: pain (VAS/NPS), TCNS, MNSI, sural NCV, and intra-epidermal nerve fiber density (IENFD) on skin biopsy — the last being the strongest structural evidence.
- Regulatory: No FDA-approved cell therapy for DPN as of mid-2026. All programs remain investigational.
2. Umbilical cord (Wharton's jelly) MSC — off-the-shelf allogeneic option
Wharton's jelly-derived MSCs (WJ-MSC) avoid the age-related potency drop of autologous bone marrow in diabetic patients. Early-phase human data — including small-fiber neuropathy cohorts — report increases in IENFD, pain reduction, and a clean safety profile with intravenous or intra-arterial delivery. This is the most promising off-the-shelf path for scaling treatment beyond specialty centers.
3. CD34+ progenitor cells and the diabetic foot
In diabetics with combined neuropathy and critical limb ischemia, autologous CD34+ / bone-marrow mononuclear cell programs have shown improvements in limb perfusion, ulcer closure, and sensory symptoms. This is the most mature regenerative pathway for the diabetic foot complex and directly relevant to painful DPN patients with vascular compromise.
4. Exosomes, iPSC-Schwann cells, and next-generation biologics
MSC-derived exosomes deliver the neurotrophic and anti-inflammatory cargo of stem cells without the cells themselves — strong preclinical results in diabetic rodents, but human data is limited to small case series and Phase I feasibility work. iPSC-derived Schwann cells for direct myelin repair are earlier still — a 2028–2032 horizon.
Consolidated status table
| Condition | Lead program | Stage | Headline result |
|---|---|---|---|
| Painful diabetic peripheral neuropathy | Autologous BM-MSC (intramuscular, lower limb) | Phase II RCTs | Pain (VAS) ↓, TCNS ↓, NCV ↑ vs control at 6–12 mo |
| DPN with critical limb ischemia | Autologous CD34+ / BM-MNC | Phase II | Improved perfusion, ↓ ulcer size, symptom relief |
| Diabetic small-fiber neuropathy | Umbilical cord Wharton's jelly MSC (allogeneic IV) | Phase I/II | IENFD ↑ on skin biopsy; pain ↓; safe |
| Diabetic foot ulcer + neuropathy | Adipose-derived MSC (topical / intradermal) | Phase II | Faster wound closure, sensory improvement |
| DPN (adjunct) | MSC-derived exosomes | Preclinical → early human | Nerve regeneration signal in rodents; no pivotal human data |
Bottom line. Intramuscular autologous BM-MSC and umbilical-cord WJ-MSC are the most credible cell-therapy signals in painful diabetic neuropathy today, with CD34+ programs leading in the diabetic-foot / ischemia overlap and exosomes still preclinical. No FDA-approved stem cell therapy for DPN exists as of mid-2026. Use the AI agent below to pull the latest data on any specific trial or program.